CytoSorbents Corporation — FY 2011 Form 10-K
Reporting period: Fiscal year ended December 31, 2011. This is an annual filing, not a standalone fourth-quarter financial report; the filing reports approximately $36,000 of CytoSorb sales in Q4.
Business context
CytoSorbents was a development-stage medical-device company developing blood-purification products. Its lead product, CytoSorb, received EU CE Mark approval in March 2011 and entered a controlled commercial release in selected German territories in September. The company had not received U.S. FDA approval. BetaSorb and the HemoDefend platform remained development-stage products.
Financial results and liquidity
| Metric | FY 2011 | FY 2010 |
|---|---|---|
| Revenue | $36,078 | $0 |
| Cost of goods sold / gross profit | $11,760 / $24,318 | $0 / $0 |
| Gross margin | Approximately 67% | Not applicable |
| Research and development expense | $2.888 million | $1.757 million |
| Net loss | $5.482 million | $2.909 million |
| Net loss available to common shareholders | $8.569 million | $5.086 million |
| Net cash used in operations | $3.829 million | $2.477 million |
At year-end, cash and cash equivalents were $1.187 million, current assets were $1.697 million, current liabilities were $1.528 million, and total liabilities were $1.804 million. Convertible notes had a reported carrying value of approximately $571,000, net of debt discounts. Stockholders’ equity was $318,000, compared with a $485,000 deficiency a year earlier. Accumulated deficit was $92.558 million.
Preferred-stock dividends were $3.087 million in 2011, primarily noncash, and increased the loss attributable to common shareholders. The filing reports no operating cash flow margin or meaningful operating margin given the company’s early commercial stage.
Material changes versus 2010
- Revenue began with limited Q4 product sales; the company cautioned that significant revenue was not expected before a broader launch.
- Net loss increased to $5.482 million from $2.909 million. R&D expense rose to $2.888 million from $1.757 million; general and administrative expense also increased.
- Operating cash use increased to $3.829 million from $2.477 million. Year-end cash rose modestly to $1.187 million from $1.056 million, supported by financing.
- Common shares outstanding increased from 122.8 million to 177.6 million during 2011; 189.1 million were outstanding as of March 28, 2012.
Outlook, risks and unusual items
- Management planned a broader European sales launch, initially across Germany and subsequently other EU markets, beginning in Q2 2012. Plans for further commercialization and studies were expressly dependent on adequate funding and continued positive clinical results.
- The 100-patient European Sepsis Trial reported no serious device-related adverse events in more than 300 treatments. In the 43 patients enrolled under electronic randomization, cytokines declined by an average of 30–50% over seven days. Post-hoc analyses found lower mortality in small high-risk subgroups; the study was not powered to establish mortality benefit, and an earlier enrollment group had randomization bias.
- The company reported $1.187 million of year-end cash against $1.528 million of current liabilities. Management estimated funds would last into Q3 2012, but the auditor highlighted substantial doubt about the company’s ability to continue as a going concern. The company expected continuing losses and required additional financing.
- A new Lincoln Park Capital agreement allowed, subject to conditions, purchases of up to $8.5 million of common stock over 32 months. The facility could provide working capital but would be dilutive and depended on market price and other terms. After year-end, the company also issued $700,000 of 12-month notes bearing 8% interest and convertible into equity.
- Other material risks include uncertain FDA and additional-market approvals, clinical and commercial adoption, manufacturing scale-up, reimbursement, competition, intellectual-property disputes, and preferred-stock terms. Series A and B preferred stock carry 10% dividends, with potential increases to 20% upon specified defaults; Series B has senior liquidation rights and potential redemption provisions.
- In December 2011, the company received a $100,000 U.S. Army Phase I SBIR award for trauma-related development. A proposed DARPA award was still subject to contract negotiations, with no assurance of completion.
Important facts for investors to verify
- Reconcile the filing’s differing descriptions of post-year-end LPC proceeds: MD&A cites approximately $850,000, while the subsequent-events note reports approximately $900,000.
- Review cash runway, operating cash burn, current liabilities, debt maturities and the terms and availability of LPC funding; financing needs may result in further dilution.
- Assess the full Sepsis Trial data, including the randomization issue, the small post-hoc mortality subgroups and the distinction between cytokine reduction and proven clinical benefit.
- Confirm timing and execution of the planned Q2 2012 broader launch, early commercial demand, reimbursement arrangements and the ability to scale manufacturing.
- Track share-count dilution from common-stock sales, convertible notes, preferred-stock conversions, options and warrants, as well as preferred dividends and default-related provisions.